"Illumina/TruSight Tumor 170 Kit, For Use with NextSeq (24 Samples)/OP-101-1003/1 Ea

" OP-101-1003 Illumina 產(chǎn)品編號(hào)： OP-101-1003美  元  價(jià)： $0.00會(huì)  員  價(jià)： 待定品       牌： Illumina產(chǎn)       地： 美國(guó)公       司： Illumina, Inc.產(chǎn)品分類： 其它>其它試劑>芯片公司分類： Clinical Research Products "Product Highlights:

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

Comprehensive Coverage of Cancer-Related Variants

Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.

Accurate Results from Low-Quality Samples1

Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.

Integrated, Streamlined Workflow

DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/CDNA synthesis.

Specifications:

Assay Time ~2 days (Library Prep)

Hands-On Time ~10.5 hours

Input Quantity 40 ng DNA and/or RNA

Method Targeted RNA Sequencing,Targeted DNA Sequencing

Variant Class Single Nucleotide Polymorphisms (SNPs),Gene Fusions,Somatic Variants,Structural Variants,Insertions-Deletions (indels),Copy Number Variants (CNVs)

Specialized Sample Types FFPE,Low Input

System Compatibility NextSeq 550,NextSeq 500,HiSeq 2500

Technology Sequencing

Species Category Human

Cancer Type Solid Tumor

Scientific Posters:

AACR 2017: TruSight Tumor 170 and Tumor Mutational Burden

Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.

Learn More

AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples

Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.

Learn More

AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

Learn More

AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples

Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.

Learn More"

Illumina公司，致力于新一代測(cè)序和芯片技術(shù)的生產(chǎn)與開發(fā)，提供產(chǎn)品與應(yīng)用資訊

Illumina公司創(chuàng)立于1998年4月，是遺傳變異和生物學(xué)功能分析領(lǐng)域的優(yōu)秀的產(chǎn)品、技術(shù)和服務(wù)供應(yīng)商。通過(guò)幫助客戶加快實(shí)現(xiàn)生物信息的采集、分析和應(yīng)用，來(lái)改善人類健康。

Sequencing Kits/ Microarray Kits/Informatics Products/ Clinical Research Products/In Vitro Diagnostic/ Products/Molecular Biology Reagents/ Accessory Products

Illumina公司基因芯片、二代測(cè)序NGS測(cè)序儀及相關(guān)測(cè)序試劑盒等產(chǎn)品

咨詢illumina MiSeq測(cè)序試劑盒等產(chǎn)品歡迎您致電 上海易匯生物科技有限公司：1850 1609 238張經(jīng)理